CN104435164A - Sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases - Google Patents

Sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases Download PDF

Info

Publication number
CN104435164A
CN104435164A CN201410626334.XA CN201410626334A CN104435164A CN 104435164 A CN104435164 A CN 104435164A CN 201410626334 A CN201410626334 A CN 201410626334A CN 104435164 A CN104435164 A CN 104435164A
Authority
CN
China
Prior art keywords
pharmaceutical composition
blood
radix paeoniae
paeoniae rubra
rhizoma chuanxiong
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410626334.XA
Other languages
Chinese (zh)
Inventor
李文军
骆均勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHENGDU GUORUI PHARMACEUTICAL TECHNOLOGY Co Ltd
Original Assignee
CHENGDU GUORUI PHARMACEUTICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHENGDU GUORUI PHARMACEUTICAL TECHNOLOGY Co Ltd filed Critical CHENGDU GUORUI PHARMACEUTICAL TECHNOLOGY Co Ltd
Priority to CN201410626334.XA priority Critical patent/CN104435164A/en
Publication of CN104435164A publication Critical patent/CN104435164A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. The sargentgloryvine-stem-containing pharmaceutical composition is prepared from raw materials including radix paeoniae rubra, rhizoma chuanxiong, sargentgloryvine stems, herba erigeromtis and borneol. The pharmaceutical composition not only has the effects of promoting blood circulation to remove blood stasis as well as tonifying qi and activating blood circulation, but also has a better effect on treating ischemic cerebrovascular diseases.

Description

A kind of pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease containing Caulis Sargentodoxae
Technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, specifically Radix Paeoniae Rubra, Rhizoma Chuanxiong, Caulis Sargentodoxae, Herba Erigerontis and Borneolum Syntheticum are the pharmaceutical composition that raw material is made.
Background technology
Cardiovascular and cerebrovascular disease is middle-aged and elderly people common disease, and especially old people's sickness rate of more than 60 years old is high, and wherein the most anxious with cerebral infarction morbidity again, change is larger, and mortality rate is the highest.The traditional Chinese medical science thinks that cerebral infarction is except this basic pattern of syndrome of syndrome of blood stasis, and all the other different TCM syndrome types are: blood stasis due to qi deficiency, stagnation of phlegm blood stasis, yang hyperactivity wind-transformation, expectorant thermal resistance network etc.According to clinical observation, old stroke patient is common with blood stagnancy due to deficiency of QI.The hemorheological many index of blood stagnancy due to deficiency of QI type is apparently higher than other pattern of syndrome, and this is because old people's visceral-qi void declines, insufficiency of vital energy and blood, and venation is hollow, and QI and blood numbness hinders, and blood is more easily in hypercoagulability, thus result in the generation of cerebrovascular.
Summary of the invention
Object of the present invention is just to provide a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, this pharmaceutical composition can activating blood circulation to dissipate blood stasis, again can replenishing qi and promoting blood flow, QI and blood is ruled together, and promotes the effects such as the mutual coordination between body fluid and QI and blood, curative effect is significantly improved.
In order to realize foregoing invention object, the invention provides following technical scheme:
Treat a pharmaceutical composition for cardiovascular and cerebrovascular disease, it is raw material composition primarily of Radix Paeoniae Rubra, Rhizoma Chuanxiong, Caulis Sargentodoxae, Herba Erigerontis and Borneolum Syntheticum.
According to the relation between qi-blood-body fluid, " the capable then blood of gas ", " stagnation of QI is blood stasis then ", the deficiency of vital energy can not handsome blood, then hematogenous blockage and the stasis of blood is stagnant, treats apoplexy, establish just for " blood stasis due to qi deficiency " pathogenesis with tonifying QI and activating blood circulation to eliminate blood stasis ruling by law.In Traditional Chinese medicine composition formula of the present invention, Radix Paeoniae Rubra, bitter in the mouth, cold nature.Return Liver Channel.Clearing away heat and cooling blood, eliminating stasis to stop pain.For maculae caused by violent heat pathogen, hematemesis and epistaxis, conjunctival congestion and swelling pain, hypochondriac pain due to stagnation of liverQI, amenorrhea dysmenorrhea, lump in the abdomen is suffered from abdominal pain, injury from falling down, carbuncle skin infection.Rhizoma Chuanxiong, acrid in the mouth, warm in nature; Return liver, gallbladder, heart channel.Gas perfume rises loose, has blood-activating and qi-promoting, effect of wind-expelling pain-stopping.Be used for the treatment of menoxenia, dysmenorrhea, amenorrhea, difficult labour, retention of placenta, lochia is suffered from abdominal pain, lump, heart pain in chest and hypochondrium, and traumatic injury swells and ache, headache vertigo and head dark, anemofrigid-damp arthralgia, numb limbs and tense tendons, the symptoms such as ulcer sores.Caulis Sargentodoxae, bitter in the mouth, property is put down.There is the eliminating carbuncle that relieves internal heat, promoting blood circulation to remove obstruction in the collateral, the effect of wind dispelling insecticide.Control acute and chronic appendicitis, rheumatic arthralgia, bloody dysentery, stranguria with blood, menoxenia, infantile malnutrition, worm pain, injury from falling down.Herba Erigerontis, acrid in the mouth, micro-hardship, warm in nature.Expelling cold and relieving exterior syndrome, expelling wind and removing dampness, activating collaterals to relieve pain.For headache due to common cold, toothache, stomachache, rheumatalgia, the paralysis that cerebrovas-cularaccident causes, osteomyelitis.Borneolum Syntheticum acrid in the mouth, hardship, be slightly cold; GUIXIN, liver, lung meridian; Delicate fragrance a surname is loose, has refreshment of having one's ideas straightened out, the loose poison of heat clearing away, effect of improving acuity of vision and removing nebula.Cure mainly calentura unconsciousness due to high fever, apoplexy syncope due to accumulation of phlegm infantile convulsion, heat-damp in summer hoodwinks key clearly, and sore throat is deaf, and aphtha tooth swells, carbuncle sore infantile malnutrition hemorrhoid, conjunctival congestion and swelling pain, pterygium.According to modern Chinese medicine pharmacology, coordinating the actions of various ingredients in a prescription, makes Patients with Cardiovascular/Cerebrovascular Diseases supply vigour, eliminates blood stasis, with the capable band blood of gas, prevents disease relapse, effectively treats the cardiovascular and cerebrovascular disease that various blood stagnancy due to deficiency of QI causes.Preferably only adopt above five kinds of compositions.
Preferably, in pharmaceutical composition of the present invention, the ratio of each component is: Radix Paeoniae Rubra 5-30 part, Rhizoma Chuanxiong 1-8 part, Caulis Sargentodoxae 1-10 part, Herba Erigerontis 1-8 part, Borneolum Syntheticum 0.01-1 part.Radix Paeoniae Rubra clearing away heat and cooling blood, eliminating stasis to stop pain, Rhizoma Chuanxiong, blood-activating and qi-promoting, wind-expelling pain-stopping, Caulis Sargentodoxae promoting blood circulation to remove obstruction in the collateral, is aided with Herba Erigerontis inducing diaphoresis to dispel wind, dehumidifies active, and Borneolum Syntheticum is had one's ideas straightened out refreshment, the loose poison of heat clearing away.Chinese medicine composition of the present invention can be had one's ideas straightened out refreshment, dredging collateral dissipating blood stasis, and Eradicates is except blood stasis, and activation vim and vigour running, prevents the deficiency of vital energy from recurring.Effectively realize the collaborative facilitation between kinds of traditional Chinese medicines, improve the effect for the treatment of cardiovascular and cerebrovascular disease greatly.
Preferably, in pharmaceutical composition of the present invention, the ratio of each component is: Radix Paeoniae Rubra 10-20 part, Rhizoma Chuanxiong 1-5 part, Caulis Sargentodoxae 2-8 part, Herba Erigerontis 1-5 part, Borneolum Syntheticum 0.01-0.05 part.In conjunction with the proportioning of the preferred each component of clinical research experience, improve mutual promoting action, reduce the toxic and side effects that medicine is unnecessary.
Most preferred, in pharmaceutical composition of the present invention, the ratio of each component is: Radix Paeoniae Rubra 15 parts, Rhizoma Chuanxiong 3 parts, Caulis Sargentodoxae 5 parts, Herba Erigerontis 3 parts, Borneolum Syntheticum 0.03 part.Select the Chinese medicine composition proportioning of aforementioned proportion, best at therapeutic effect, after medication, patient gets well fast, and the cardiovascular and cerebrovascular disease relapse rate caused by blood stasis due to qi deficiency is extremely low.
Pharmaceutical composition of the present invention, the method by oral, external, injection, infiltration, absorption, physics or chemistry mediation imports body as muscle, Intradermal, subcutaneous, vein or mucosal tissue; Or to be mixed by other material or to import body after wrapping up.
Further, pharmaceutical composition of the present invention, adds medicine acceptable carrier or adjuvant when being prepared into medicament, make pharmaceutically acceptable dosage form.
Pharmaceutical composition of the present invention, according to use needs, can by current usual manner, by described active drug composition auxiliary adding ingredient corresponding to acceptable in medicine, as disintegrating agent, excipient, lubricant, binding agent, filler etc., jointly be prepared into operational, comprise the oral type pharmaceutical preparation of the common formulations such as tablet, drop pill, capsule, micropill.
The cardiovascular and cerebrovascular disease that medicine of the present invention is controlled mainly comprises cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia, nerve injury, senile dementia, parkinsonism etc.Be particularly useful for the prevention and therapy of ischemia apoplexy.
Compared with prior art, beneficial effect of the present invention:
In Chinese medicine composition of the present invention, Radix Paeoniae Rubra clearing away heat and cooling blood, eliminating stasis to stop pain, Rhizoma Chuanxiong, blood-activating and qi-promoting, wind-expelling pain-stopping, Caulis Sargentodoxae promoting blood circulation to remove obstruction in the collateral, is aided with Herba Erigerontis inducing diaphoresis to dispel wind, dehumidifies active, and Borneolum Syntheticum is had one's ideas straightened out refreshment, the loose poison of heat clearing away.So Chinese medicine composition of the present invention can be had one's ideas straightened out refreshment, dredging collateral dissipating blood stasis, Eradicates is except blood stasis, and activation vim and vigour running, prevents the deficiency of vital energy from recurring.
Detailed description of the invention
Pharmaceutical composition of the present invention can adopt but be not limited to following methods:
Preparation method one: get Radix Paeoniae Rubra, Rhizoma Chuanxiong, Caulis Sargentodoxae and Herba Erigerontis in proportion, pulverized 40 mesh sieves respectively, and Borneolum Syntheticum mix homogeneously, after adding the acceptable auxiliary element of pharmacy as required, made the oral type pharmaceutical preparatioies such as tablet, capsule or micropill.
Preparation method two: by Radix Paeoniae Rubra, Rhizoma Chuanxiong, Caulis Sargentodoxae and Herba Erigerontis alcohol reflux, extracting solution is concentrated into dry, obtains extract.By this extract and Borneolum Syntheticum mixing, after adding the acceptable auxiliary element of pharmacy as required, make the oral type pharmaceutical preparatioies such as tablet, capsule, drop pill or micropill.
Preparation method three:
Prepare the method for Chinese medicine composition of the present invention, comprise the following steps:
(1) get Radix Paeoniae Rubra, add the water of 2-3 times of volume, reflux, extract, 1-2 hour, repeat to extract 3-5 time, merge extractive liquid, is concentrated into dry, obtains Radix Paeoniae Rubra extract.
(2) Ligusticum chuanxiong Hort is got, by the high concentration ethanol reflux, extract, 2 ~ 3 times of 8-10 times of volume, each 1 ~ 2 hour, extracting liquid filtering, merging filtrate, concentrating under reduced pressure obtains extractum, be dissolved in water, sucking filtration, filtrate crosses macroporous resin column (volume ratio of extractum and resin is 1:15-1:20), first wash with water to effluent colourless, water elution liquid is discarded, and then uses 30% ~ 40% ethanol elution, ethanol elution decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract.
(3) Caulis Sargentodoxae section is got, add the alcohol reflux 1-2 hour of 30% ~ 50% of 1 ~ 2 times of volume ratio, filter, collect filtrate, repeat to extract once, merging filtrate, filtrate crosses polyamide column, first rinses colourless to effluent with water, use straight alcohol eluting again, collect ethanol elution, be concentrated into dry, obtain Caulis Sargentodoxae extract.
(4) Herba Erigerontis medical material is got, preferably through the preliminary Herba Erigerontis pulverized, add the high concentration ethanol of 4 ~ 6 times amount, reflux, extract, 1 ~ 2 time, each 1 ~ 2 hour, merge extractive liquid, reclaim ethanol to paste, add 0.1% sodium hydroxide to dissolve, filter, the saturated n-butanol extraction of filtrate water.After water layer regulates pH=2 ~ 3, then with water-saturated n-butanol extraction, merge n-butyl alcohol liquid, be concentrated into dry, obtain Herba Erigerontis extract.
(5) mix in proportion through the raw material of above-mentioned steps process and Borneolum Syntheticum, make tablet or capsule.The acceptable adjuvant of appropriate pharmacy can be added according to actual needs.
High concentration ethanol of the present invention or dense ethanol refer to the ethanol water of percent by volume more than 60%.Described Diluted Alcohol refers to the ethanol water of percent by volume below 25%.
Wherein most preferably preparation method three, preparation method three is according to different medicines characteristic separately, select suitable extracting method farthest to be extracted by the effective ingredient in medicinal raw material, avoid the impact of the impurity of toxic side effect, so most preferably preparation method three.
The curative effect of medicine of the present invention and advantage thereof are proved by following pharmacodynamics test:
Test one: pharmacodynamics test rat " rabbit brain powder-macromolecule glucosan " being caused to the therapeutical effect of cerebral infarction
Principle: because cardiovascular and cerebrovascular disease all can cause hemorheological change, so medicine causes the therapeutical effect of cerebral infarction pharmacodynamics test to rat " rabbit brain powder-macromolecule glucosan " can be designed, to measure the change that whole blood viscosity under different shear rate investigates hemorheological property after cerebral infarction, investigate erythrocyte deformability with red blood cell protein ringer solution viscosity, thus investigate medicine to the therapeutical effect of cardiovascular and cerebrovascular disease.
Material: animal: rat, body weight 250-350g, male and female are regardless of.Equipment: cone and plate viscometer, centrifuge, scale centrifuge tube, eye scissors, ophthalmic tweezers and conventional operating theater instruments, 0 trumpeter's art silk thread, vascular clamp etc.
Medicine and reagent: application medicine 1:(Radix Paeoniae Rubra 15 parts, Rhizoma Chuanxiong 3 parts, Caulis Sargentodoxae 5 parts, Herba Erigerontis 3 parts, Borneolum Syntheticum 0.03 part, adopt preparation method three to be prepared into tablet);
Application medicine 2:(Radix Paeoniae Rubra 16 parts, Rhizoma Chuanxiong 3 parts, Caulis Sargentodoxae 5 parts, Herba Erigerontis 3 parts, Borneolum Syntheticum 0.02 part, adopt preparation method two to be prepared into tablet);
Application medicine 3:(Radix Paeoniae Rubra 10 parts, Rhizoma Chuanxiong 4 parts, Caulis Sargentodoxae 3 parts, Herba Erigerontis 5 parts, Borneolum Syntheticum 0.03 part.Preparation method one is adopted to be prepared into tablet);
Control drug 1:(Rhizoma Chuanxiong 4 parts, Caulis Sargentodoxae 3 parts, Herba Erigerontis 5 parts, Borneolum Syntheticum 0.03 part, adopt preparation method two to be prepared into tablet);
Control drug 2:(Radix Paeoniae Rubra 16 parts, Rhizoma Chuanxiong 3 parts, Caulis Sargentodoxae 5 parts, Borneolum Syntheticum 0.02 part, adopt preparation method one to be prepared into tablet);
Control drug 3:(Radix Paeoniae Rubra 15 parts, Caulis Sargentodoxae 5 parts, Herba Erigerontis 3 parts, Borneolum Syntheticum 0.03 part, adopt preparation method two to be prepared into tablet);
With commercially available Breviscapini injection for positive drug contrasts; Rabbit brain powder (rabbit brain powder thromboplastin powder).Get the rabbit brain powder between sub-sieve 120-150 order, granule is 100-120m.Macromolecule glucosan: molecular weight 5,000,000.The preparation of suppository: 25mg rabbit brain powder is mixed in 10% macromolecule dextran solution 100ml, is placed in 37 DEG C of water-baths 40 minutes.Then ,-18 DEG C of refrigerators are put in for subsequent use.Rapid Medical ZT glue.BSA, ringer solution.Heparin sodium: add test tube by 20u/ml blood dosage, less than 40 DEG C dry for standby.
Test method: 1, rat cerebral infarction model preparation: rat etherization, lie on the back fixing, skin cropping is sterilized, cervical incision, and on the left of being separated, neck always beats one's brains, neck is interior, external carotid artery.Folder closes external carotid artery, common carotid artery proximal part respectively.A vascular clamp is pressed from both sides again at distal end place.After suppository is shaken up, lunge common carotid artery with 0.25ml syringe by 0.03ml/100g rat dosage, open distal end vascular clamp, suppository is injected.Then, folder closes common carotid artery distal end, extracts syringe needle, bonds pin hole with medical adhesive.Decontrol the vascular clamp of common carotid artery distal end, proximal part, external carotid artery after 1 minute successively, recover blood flow, cleaning wound, skin suture.
Medicine affects the hemorheology of different time after cerebral infarction: rat is divided into 2 hours groups, 3 days groups, 9 days groups, often group is further divided into administration group (application medicine 1 ~ 3 group or control drug 1 ~ 3 group+animal model group), normal saline group (normal saline+animal model group), sham operated rats (matched group), often organizes 12 rats.Administration group, normal saline group impose operation technique all as stated above, and sham operated rats operation technique is identical, but not injected plug agent, replace suppository with normal saline, be injected in internal carotid artery.
Administration group is in operation consent 3 days oral drugs (the application's medicine, control drug) 1.42g/Kg.Positive drug is in operation consent 1 hour intraperitoneal injection of drugs 1.0mg/Kg.Normal saline group injects commensurability normal saline.Sham operated rats does not inject any medicine.Every morning administration 1 time after 3 days groups and 9 days groups, for three days on end or 9 days.
2 hours after surgery, the 3rd day, the 9th day respectively, by rat anesthesia (25% urethane 0.3ml/100g body weight, lumbar injection), right common carotid artery blood-letting, in heparin test tube, measured the whole blood viscosity under different shear rate with cone and plate viscometer in 2 hours.Again that whole blood is centrifugal with 1500rpm, suck upper plasma.Then 0.25% bovine serum albumin-ringer solution rinsing erythrocyte three times is used, centrifugal 10 minutes of each 1500rpm.Finally, be in vitro mixed with erythrocyte at scale: albumen appoints the red blood cell protein ringer solution of liquid=6:4, measure its viscosity at 20 seconds under-1 shear rate.Using red blood cell protein ringer solution viscosity as erythrocyte deformability.All experiments are all carried out under 25 DEG C of constant temperature, carry out statistical test to experimental result.Concrete numerical value and the results are shown in Table one, table two.
Table one: the whole blood viscosity of different time after rat cerebral infarction is affected (unit: mPa.s)
From table one result of the test, after blocking latter 2 hours, whole blood viscosity respectively organizes equal no significant difference.When blocking 3 days, normal saline group is compared with sham operated rats, and whole blood viscosity rises (P<0.05), and animal model modeling success is described.Each administration group all can reduce whole blood viscosity to some extent, and wherein with the application's effect of drugs best (P<0.01, compared with normal saline group), control drug effect is taken second place.When blocking after 9 days, normal saline group is still abnormality with sham operated rats ratio, hemorheology, and whole blood viscosity increases the weight of further.Each administration group and normal saline group ratio, whole blood viscosity declines, and statistical procedures has significant, and wherein with the application's effect of drugs best (P<0.01), control drug effect is taken second place.
Table two: on the impact (unit: mPa.s) of different time erythrocyte-albumen ringer solution viscosity
From table two result of the test, after blocking latter 2 hours, normal saline group and administration group erythrocyte deformability decline, and each administration group is slightly lower than normal saline group numerical value, but effect is very unobvious.When blocking 3 days, normal saline group is compared with sham operated rats, and erythrocyte deformability declines further, all can erythrocyte deformability be stoped to a certain extent to decline in each administration group, the application's effect of drugs best (P<0.01).When blocking after 9 days, normal saline group and sham operated rats ratio, erythrocyte deformability further declines.Each administration group and normal saline group ratio, all can improve and stop the decline of erythrocyte deformability, statistical procedures has significant (P<0.01), wherein can strengthen erythrocyte deformability with the application's medicine.
In sum, perform the operation after 2 hours, rat has hemorheological exception.Infraction 3-9 days, Abnormal Blood Rheology increases the weight of further, shows as whole blood viscosity and raises, degradation under erythrocyte deformability.The application's medicine can play and improve hemorheological property effect after cerebral infarction, after the 3rd day, then can correct abnormal hemorheology change significantly.And successful is better than control drug, be also better than commercially available Breviscapini injection.
Test two: on senile rat in the thrombotic impact of body
Principle: use unidirectional current continued stimulus common carotid artery 7 minutes, cause blood vessel internal membrane damage, activate platelet and blood coagulation system, simultaneously vascular endothelial cell injury, makes the synthesis of PGI2 and release reduce, causes in carotid artery vascular and form mixed thrombus gradually.When carotid artery vascular endogenous cause of ill thrombosis during plug flow, then blood vessel distal temperature bust.By temperature sensor monitors blood vessel surface variations in temperature, by instrument automatic alarm, record to sudden temperature drop required time from stimulation, claim duration of congestion OT, i.e. thrombus formation time.Time is shorter, represents and more easily forms thrombosis; Otherwise the time is longer, represents and more not easily form thrombosis.
Senile rat can self-assembling formation blood stasis body constitution, easily forms thrombus in vivo.Young rat then not easily forms thrombosis.Therefore be positive control with senile rat in test, take young rat as negative control.
Material: male rat.Younger group Mus 3-4 in the age month, about body weight 250g.Old group Mus 24-27 in the age month, about body weight 500g.Equipment: rat operation platform, operating scissors, ophthalmic tweezers, mosquito forceps, mosquito clamp, rat oral gavage syringe needle, instrument for detecting internal thrombosis.Medicine and reagent: the application's medicine and control drug are with test one, and dosage is 1.42g/Kg; 20mg/ml Nembutal sodium solution; Normal saline.
Method: only give experimental group every day old group rat oral gavage 2ml/, positive controls senile rat and negative control group young rat gavage distilled water 2ml/ only, continuous 14 days.Drug withdrawal fasting on the same day.Lumbar injection 20mg/ml pentobarbital sodium 0.2ml/100g next day (body weight).Cut skin of neck, be separated right carotid artery, transfer stimulating electrode at carotid artery near-end, far-end transfers the temperature gauge head connecting instrument.Open instrument switch, give 1.5mV galvanic stimulation 7 minutes to damage carotid artery endotheliocyte by stimulating electrode, along with carotid canal intracavity thrombosis is formed gradually, blood flow is blocked gradually, and the temperature of carotid artery far-end declines gradually.When blood flow blocks completely, sudden temperature drop, instrument alarm, display duration of congestion OT, the OT time is shorter, more easily forms thrombosis; The OT time is longer, more not easily forms thrombosis.
Statistical test is carried out to experimental result.Concrete numerical value and the results are shown in Table three.
Table three: on senile rat in the thrombotic impact of body
From table three result of the test, senile rat OT is obviously short compared with young rat, illustrates and easily forms thrombosis.Administration group all can significant prolongation OT, and the application's effect of drugs better (P<0.01).
Above result shows, the application's medicine is effective compared with control drug.
Below in conjunction with detailed description of the invention, the present invention is described in further detail.Percentage ratio not specified in the present invention is all weight percentage.
Embodiment 1
Get Radix Paeoniae Rubra 15kg, Rhizoma Chuanxiong 3kg, Caulis Sargentodoxae 5kg and Herba Erigerontis 3kg and pulverize 40 mesh sieves respectively, and Borneolum Syntheticum 0.03kg mix homogeneously, make capsule.
Embodiment 2
Obtain mixed powder by the method for embodiment 1, make capsule casing material with gelatin, be pressed into soft capsule.
Embodiment 3
Get Radix Paeoniae Rubra 20kg, Rhizoma Chuanxiong 1kg and Caulis Sargentodoxae 8kg alcohol reflux, extracting solution is concentrated into dry, obtains mixed extract one.By Herba Erigerontis 5kg water boiling and extraction, extracting solution is concentrated into dry, obtains extract two.Above-mentioned pretreated raw material and Borneolum Syntheticum 0.01kg are mixed, adds appropriate auxiliary agent, tabletted.
Embodiment 4
Proportioning raw materials consumption is identical with embodiment 3, just Radix Paeoniae Rubra 20kg, Rhizoma Chuanxiong 1kg and Caulis Sargentodoxae 8kg with 40% of 3 times of volumes alcohol reflux 3 hours, repeat extraction 4 times, extracting solution is concentrated into dry, obtains extract one.All the other steps are also identical with embodiment 3.
Embodiment 5
Implementation process is with embodiment 1, and just raw material dosage is: Radix Paeoniae Rubra 30kg, Rhizoma Chuanxiong 8kg, Caulis Sargentodoxae 10kg, Herba Erigerontis 8kg, Borneolum Syntheticum 1kg.
Embodiment 6
Implementation process is with embodiment 1, and just raw material dosage is: Radix Paeoniae Rubra 5kg, Rhizoma Chuanxiong 1kg, Caulis Sargentodoxae 2kg, Herba Erigerontis 2kg, Borneolum Syntheticum 0.01kg.
Embodiment 7
Get Radix Paeoniae Rubra 10kg, Rhizoma Chuanxiong 5kg, Caulis Sargentodoxae 2kg, Herba Erigerontis 1kg, Borneolum Syntheticum 0.05kg, mixed after pulverizing 60 mesh sieves respectively, add appropriate forming agent, binding agent tabletted.
Embodiment 8
Get Radix Paeoniae Rubra 15kg, add the water of 3 times of volumes, reflux, extract, 2 hours, repeat extraction 4 times, merge extractive liquid, be concentrated into dry, obtain Radix Paeoniae Rubra extract.Get Rhizoma Chuanxiong 3kg, by the high concentration ethanol reflux, extract, 2 times of 10 times of volumes, each 1.5 hours, extracting liquid filtering, merging filtrate, concentrating under reduced pressure obtains extractum, be dissolved in water, sucking filtration, filtrate crosses macroporous resin column (volume ratio of extractum and resin is 1:15-1:20), first wash with water to effluent colourless, water elution liquid is discarded, and then uses 40% ethanol elution, ethanol elution decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract.Get Caulis Sargentodoxae 5kg, section, add the alcohol reflux 1 hour of 30% of 2 times of volume ratios, filter, collect filtrate, repeat to extract once, merging filtrate, filtrate crosses polyamide column, first rinse colourless to effluent with water, then use straight alcohol eluting, collect ethanol elution, be concentrated into dry, obtain Caulis Sargentodoxae extract.Get Herba Erigerontis 3kg, preferably through the preliminary Herba Erigerontis pulverized, add the high concentration ethanol of 6 times amount, reflux, extract, 2 times, each 1 hour, merge extractive liquid, reclaimed ethanol to paste, add 0.1% sodium hydroxide to dissolve, filter, the saturated n-butanol extraction of filtrate water.After water layer regulates pH=3, then with water-saturated n-butanol extraction, merge n-butyl alcohol liquid, be concentrated into dry, obtain Herba Erigerontis extract.Mix in proportion through the raw material of above-mentioned steps process and Borneolum Syntheticum 0.03kg, make tablet or capsule.The acceptable adjuvant of appropriate pharmacy can be added according to actual needs.
Embodiment 9
Get Radix Paeoniae Rubra 15kg, add the water of 2 times of volumes, reflux, extract, 1.5 hours, repeat extraction 5 times, merge extractive liquid, be concentrated into dry, obtain Radix Paeoniae Rubra extract.Get Rhizoma Chuanxiong 3kg, by the high concentration ethanol reflux, extract, 3 times of 8 times of volumes, each 2 hours, extracting liquid filtering, merging filtrate, concentrating under reduced pressure obtains extractum, be dissolved in water, sucking filtration, filtrate crosses macroporous resin column (volume ratio of extractum and resin is 1:15-1:20), first wash with water to effluent colourless, water elution liquid is discarded, and then uses 40% ethanol elution, ethanol elution decompression recycling ethanol, vacuum drying, obtains Rhizoma Chuanxiong extract.Get Caulis Sargentodoxae 5kg, section, add the alcohol reflux 2 hours of 50% of 2 times of volume ratios, filter, collect filtrate, repeat to extract once, merging filtrate, filtrate crosses polyamide column, first rinse colourless to effluent with water, then use straight alcohol eluting, collect ethanol elution, be concentrated into dry, obtain Caulis Sargentodoxae extract.Get Herba Erigerontis 3kg, preferably through the preliminary Herba Erigerontis pulverized, add the high concentration ethanol of 4 times amount, reflux, extract, 2 times, each 1.5 hours, merge extractive liquid, reclaimed ethanol to paste, add 0.1% sodium hydroxide to dissolve, filter, the saturated n-butanol extraction of filtrate water.After water layer regulates pH=3, then with water-saturated n-butanol extraction, merge n-butyl alcohol liquid, be concentrated into dry, obtain Herba Erigerontis extract.Mix in proportion through the raw material of above-mentioned steps process and Borneolum Syntheticum 0.03kg, make tablet or capsule.The acceptable adjuvant of appropriate pharmacy can be added according to actual needs.

Claims (4)

1. treat a pharmaceutical composition for cardiovascular and cerebrovascular disease, it is characterized in that being prepared from primarily of Radix Paeoniae Rubra, Rhizoma Chuanxiong, Caulis Sargentodoxae, Herba Erigerontis and Borneolum Syntheticum.
2. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 1, it is characterized in that the ratio of each component is: Radix Paeoniae Rubra 5-30 part, Rhizoma Chuanxiong 1-8 part, Caulis Sargentodoxae 1-10 part, Herba Erigerontis 1-8 part, Borneolum Syntheticum 0.01-1 part.
3. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 2, it is characterized in that the ratio of each component is: Radix Paeoniae Rubra 10-20 part, Rhizoma Chuanxiong 1-5 part, Caulis Sargentodoxae 2-8 part, Herba Erigerontis 1-5 part, Borneolum Syntheticum 0.01-0.05 part.
4. treat the pharmaceutical composition of cardiovascular and cerebrovascular disease as claimed in claim 3, it is characterized in that the ratio of each component is: Radix Paeoniae Rubra 15 parts, Rhizoma Chuanxiong 3 parts, Caulis Sargentodoxae 5 parts, Herba Erigerontis 3 parts, Borneolum Syntheticum 0.03 part.
CN201410626334.XA 2014-11-10 2014-11-10 Sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases Pending CN104435164A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410626334.XA CN104435164A (en) 2014-11-10 2014-11-10 Sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410626334.XA CN104435164A (en) 2014-11-10 2014-11-10 Sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

Publications (1)

Publication Number Publication Date
CN104435164A true CN104435164A (en) 2015-03-25

Family

ID=52882426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410626334.XA Pending CN104435164A (en) 2014-11-10 2014-11-10 Sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

Country Status (1)

Country Link
CN (1) CN104435164A (en)

Similar Documents

Publication Publication Date Title
CN102847063B (en) Traditional Chinese medicinal composition for treating qi and blood deficiency blood stasis type diabetic feet, and its preparation method
CN105031020A (en) Decoction medicine for treating thrombophlebitis and preparation method for decoction medicine
CN104173748A (en) Orally taken medicine for treating cancer of pharynx and preparation method thereof
CN100420454C (en) Pharmaceutical composition for treating apoplexy and preparation method thereof
CN101987112B (en) Medicine composition for treating cardio-cerebrovascular diseases and preparation method thereof
CN102961517B (en) Pharmaceutical composition for treating cardiovascular and cerebrovascular disease
CN102940680B (en) Medicine composition for treating cardia-cerebrovascular diseases
CN102940668B (en) Medicine composition for treating cardia-cerebrovascular diseases
CN103417716B (en) Hypoglycemic Tongluo tablet for treating diabetic peripheral neuropathy
CN104367630A (en) American ginseng-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
CN102940675B (en) Medicine composition for treating cardia-cerebrovascular diseases
CN104367656A (en) Hawthorn leaf-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
CN104721556A (en) Traditional Chinese medicine used for treating oral ulcer
CN102940669B (en) A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
CN104721559A (en) Traditional Chinese medicine composition for treating oral ulcer
CN104435164A (en) Sargentgloryvine-stem-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
CN105796927B (en) A kind of Chinese medicine composition for treating blepharospasm
CN102940657A (en) Medicine composition for treating cardia-cerebrovascular diseases
CN102940676B (en) Medicine composition for treating cardia-cerebrovascular diseases
CN102940694B (en) Medicine composition for treating cardia-cerebrovascular diseases
CN104435664A (en) Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
CN104367618A (en) Fructus choerospondiatis-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
CN102973882A (en) Traditional Chinese medicine for treating cervical spondylosis
CN104435080A (en) Ginseng-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases
CN104435074A (en) Rhodiola-rosea-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150325